STUDIES ON THE METABOLISM OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL AND URACIL CO-ADMINISTERED ORALLY TO TUMOR-BEARING RATS

被引：0

|

作者：

KAWAGUCHI, Y

NAGAYAMA, S

MASUDA, H

YASUDA, A

机构：

来源：

GANN | 1980年 / 71卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：889 / 899

页数：11

相关论文

共 50 条

[31] PHYSICAL-PROPERTIES OF PYRIMIDINE AND PURINE ANTIMETABOLITES .2. PERMEATION OF 5-FLUOROURACIL AND 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL THROUGH CELLOPHANE, COLLAGEN, AND SILICONE MEMBRANES
NAKANO, M
ARAKAWA, Y
JUNI, K
ARITA, T
CHEMICAL & PHARMACEUTICAL BULLETIN, 1976, 24 (11) : 2716 - 2722
[32] GENERAL PHARMACOLOGICAL PROPERTIES OF UFT, A NEW TYPE OF ANTICANCER AGENT CONSISTING OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL (FT) AND URACIL .1. PHARMACOLOGICAL ANALYSIS OF THE COMBINED EFFECT OF FT AND URACIL
YAMAMOTO, J
TOIDE, K
HARUNO, A
YOSHIMURA, Y
UNEMI, N
ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1981, 31-2 (08): : 1268 - 1278
[33] ADJUVANT EFFECTS OF CALMODULIN ANTAGONISTS ON ANTITUMOR-ACTIVITY OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL (FTORAFUR) AND A MIXTURE OF FTORAFUR AND URACIL (UFT) IN NUDE-MICE BEARING HUMAN OVARIAN CARCINOMAS
KIKUCHI, Y
OOMORI, K
IWANO, I
KIZAWA, I
MIYAUCHI, M
KITA, T
KUKI, E
GYNECOLOGIC ONCOLOGY, 1989, 35 (02) : 172 - 176
[34] A PROTEIN-BOUND POLYSACCHARIDE IMMUNOMODULATOR, PSK, DOES NOT SUPPRESS THE CONVERSION FROM 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL TO 5-FLUOROURACIL IN PATIENTS WITH GASTRIC-CANCER
ANAI, H
SAKAGUCHI, Y
EMI, Y
KOHNOE, S
MAEHARA, Y
SUGIMACHI, K
ANTI-CANCER DRUGS, 1991, 2 (03) : 275 - 278
[35] STUDIES ON COMBINATION THERAPY WITH 1-(TETRAHYDRO-2-FURANYL)-5-FLUOROURACIL PLUS URACIL .2. EFFECTS OF URACIL ON INVITRO METABOLISMS OF 1-(TETRAHYDRO-2-FURANYL)-5-FLUOROURACIL AND 5-FLUOROURACIL
UNEMI, N
TAKEDA, S
CHEMOTHERAPY-TOKYO, 1981, 29 (02): : 176 - 184
[36] PHYSICAL-PROPERTIES OF PYRIMIDINE AND PURINE ANTIMETABOLITES .1. EFFECTS OF SALTS AND TEMPERATURE ON SOLUBILITY OF 5-FLUOROURACIL, 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL, 6-MERCAPTOPURINE, AND THIOINOSINE
ARAKAWA, Y
NAKANO, M
JUNI, K
ARITA, T
CHEMICAL & PHARMACEUTICAL BULLETIN, 1976, 24 (07) : 1654 - 1657
[37] Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil
Ho, DH
Pazdur, R
Covington, W
Brown, N
Huo, YY
Lassere, Y
Kuritani, J
CLINICAL CANCER RESEARCH, 1998, 4 (09) : 2085 - 2088
[38] ANTICANCER DRUG DISTRIBUTION IN LYMPH AND BLOOD DURING ADJUVANT CHEMOTHERAPY AFTER SURGERY FOR GASTRIC-CARCINOMA - A STUDY WITH A COMBINED PREPARATION OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL AND URACIL
HANAUE, H
KUROSAWA, T
KITANO, Y
MIYAKAWA, S
NEMOTO, A
YAMAMOTO, H
ASAGOE, T
TAKADA, T
YASUDA, H
SHIKATA, JI
CANCER, 1987, 59 (09) : 1571 - 1576
[39] RAPID-DETERMINATION OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL IN HUMAN-BLOOD BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY
HOBARA, N
WATANABE, A
JOURNAL OF CHROMATOGRAPHY, 1978, 146 (03): : 518 - 521
[40] STUDIES ON FATE OF 1-(2-TETRAHYDROFURYL)-5-FLUOROURACIL (FT-207), A CARCINOSTATIC AGENT .3. ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM AFTER RECTAL ADMINISTRATION OF FT-207
FUJII, S
OKUDA, H
AKAZAWA, A
YASUDA, Y
KAWAGUCHI, Y
FUKUNAGA, Y
NISHIKAWA, H
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1975, 95 (06): : 732 - 740

← 1 2 3 4 5 →